Gapping up
In reaction to strong earnings/guidance: N/A
In reaction to strong earnings/guidance: N/A
M&A news:
- REXX +4.5% (Antero (AR) will acquire the company's Ohio Utica assets in the Warrior South Area for net proceeds at closing of approx. $30.0 mln)
- NVLS +4.3% (initiated a process to explore and review a range of strategic alternatives)
Select metals/mining stocks trading higher:
- MUX +1.9%, SBGL +1.6%, GFI +1.5%, SLV +1%, NEM +0.9%, GDX +0.9%, ABX +0.8%
Other news:
- CBAY +41.6% (Kowa Pharmaceuticals America announces agreement with CymaBay Therapeutics to license gout compound)
- BLPH +24.1% (receives confirmation of the FDA's acceptance of all modifications proposed by the co to its Phase 3 program for INOpulse )
- OCUL +9% (announces additional successful results for Phase 3 clinical trial of Dextenza)
- ECA +5% (anticipates production growth from its core four assets from 4Q16 to 4Q17 will be in the upper range of, or exceed, its previously indicated growth plan of 15-20% Y/Y)
- SHAK +4.6% (to Join S&P SmallCap 600)
- NVLS +4.3% (initiated a process to explore and review a range of strategic alternatives)
- KOPN +3.5% (continued strength)
- DEPO +3.2% (continued strength)
- XRX +3% (continued strength)
- RYAAY +2.2% (reports Dec traffic rose 20% YoY)
- FOLD +1.4% (announced that the National Institute for Health and Care Excellence Highly Specialised Technologies Evaluation Committee has issued a positive final evaluation determination for reimbursed patient access to Galafold)
- CC +1.2% (to join S&P MidCap 400),
Analyst comments:
- GBT +6.6% (initiated with a Overweight at JP Morgan),
- CS +3.7% (upgraded to Overweight from Equal Weight at Barclays)
- STZ +2.8% (upgraded to Buy from Underperform at BofA/Merrill )
- RDS.A +1% (upgraded to Outperform at RBC Capital Mkts)
- MO +0.9% (upgraded to Buy from Neutral at BofA/Merrill)
- PIR +0.7% (initiated with a Buy at Loop Capital)
- A +0.7% (upgraded to Overweight at Barclays)